Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label inhaled molgramostim study in autoimmune pulmonary alveolar proteinosis
NL-OMON46569Phase 3Completed
- Sponsor
- Savara
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Savara. Primary endpoints: Number of adverse events, Number of serious adverse events and 2 more. Started May 2018; status: completed.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NL-OMON46569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46569.